Selective (beta-1) blockade in congestive cardiomyopathy

Jacob, Andrew S.; Hafer, Jocelyn F.

doi:10.1016/0002-8703(83)90261-2

Cited by 4 publications

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Initiating treatment with as little as 5 mg of metoprolol daily followed by very gradual dose titration to modest levels under close clinical supervision leads to upregulation of ,-adrenoceptors which may improve the response to sympathetic stimulation during exercise (Engelmeier et al, 1986;Swedberg et al, 1979). Nevertheless, even minimal doses of a P-adrenoceptor blocker occasionally produce a low output clinical state, and this approach to treatment is not without its hazards (Anderson et al, 1985;Jacob & Hafer, 1983).…”

Section: Heart Failurementioning

confidence: 99%

Beta‐adrenoceptor partial agonists: a renaissance in cardiovascular therapy?

Waller

1990

Brit J Clinical Pharma

View full text Add to dashboard Cite

Section: Heart Failurementioning

confidence: 99%

Beta‐adrenoceptor partial agonists: a renaissance in cardiovascular therapy?

Waller

1990

Brit J Clinical Pharma

View full text Add to dashboard Cite

Use of beta-adrenoceptor blockers in patients with congestive heart failure

Panfilov¹,

Wahlqvist²,

Olsson³

1995

Cardiovasc Drug Ther

View full text Add to dashboard Cite

The beneficial effect of chronic beta-blockade in patients with congestive heart failure has been repeatedly shown since its introduction into treatment for this condition in 1975. Still this kind of therapy remains controversial, it is sometimes regarded as a therapeutic paradox, and its use is mainly limited to specialist centers. Various favorable effects of beta-blockers in patients with heart failure due to idiopathic dilated cardiomyopathy and ischemic heart disease have been demonstrated, the principal among them being reduction in energy requirements and ischemia, antiarrhythmogenic effect, improvement of diastolic function, protection of myocytes against catecholamine overload, centrally mediated increase in vagal tone, upregulation of beta-adrenergic receptors, and possible blockade of autoantibodies against beta 1-receptors. Although most of the studies used metoprolol, these effects may be relevant to certain other beta-blockers. Despite very solid pathophysiological and pharmacological rationales for the use of beta-blockade, a major obstacle for a general acceptance of this therapeutic concept is the striking contrast between hemodynamic changes during the acute effect and long-term treatment. When titrated carefully from very low doses and used with a true commitment to long-term treatment, beta-blockers have been shown to prevent further deterioration of heart failure and to improve hemodynamics, exercise tolerance, quality of life, and prognosis.

show abstract

The xamoterol experience in the treatment of heart failure

Cruickshank

1993

The American Journal of Cardiology

View full text Add to dashboard Cite

Selective (beta-1) blockade in congestive cardiomyopathy

Cited by 4 publications

References 2 publications

Beta‐adrenoceptor partial agonists: a renaissance in cardiovascular therapy?

Beta‐adrenoceptor partial agonists: a renaissance in cardiovascular therapy?

Use of beta-adrenoceptor blockers in patients with congestive heart failure

The xamoterol experience in the treatment of heart failure

Contact Info

Product

Resources

About